OrganiGram Holdings Inc.
Q1 2021 Earnings Call Transcript

Published: 12 Jan 2021

[Operator:]

Good morning. My name is Casey, and I'll be your operator today. At this time, I would like to welcome everyone to OrganiGram Holdings Inc.'s First Quarter Fiscal 2021 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. We ask that you please limit yourself to one question and one follow-up question. You may requeue if you have any further questions. As a reminder, this conference call is being recorded and a replay will be available on OrganiGram's website.

[Amy Schwalm:]

Thank you, Casey. Joining me today are OrganiGram's Chief Executive Officer, Greg Engel; Chief Financial Officer, Derrick West; and our Chief Strategy Officer, Paolo de Luca. Before we begin, I would like to remind you that today's call will include estimates and other forward-looking information from which our actual results could differ. Please review the cautionary language in today's press release regarding various factors, assumptions and risks that could cause our actual results to differ. Furthermore, during this call, we will refer to certain non-IFRS financial measures, including adjusted EBITDA and adjusted gross margin. These measures do not have any standardized meaning under IFRS and our approach in calculating these measures may differ from that of other issuers, and so are not directly comparable. Please see today's earnings report for more information about them. I will now hand the call over to Greg.

[Gregory Engel:]

Thanks, Amy. Good morning. And thank you for joining us today. This morning, we reported our first quarter fiscal 2021 results for the period ended November 30, 2020. We were pleased with meaningful growth in our adult recs sales sequentially from last quarter, strong evidence that our new products as part of our portfolio revitalization are resonating well with consumers. We're excited about the recent launch of another three strains under our Edison brand, and we have more to come in the next few quarters as we continue to reinvigorate this brand. Encouragingly, Edison was recognized as one of the most searched brands on the Ontario cannabis store website for the month of November. We've started to ramp up cultivation and staffing such that we can meet overall increased demand in the industry and for many of our new products. And we have the assets and financial strength to support our plans. In contrast to many of our peers, we generated positive cash flow from operations in Q1, the second quarter of the last three quarters with positive cash flow from ops. Since the second half of fiscal 2020, we've been extremely active, introducing new products and improving many of our existing ones. Since July, we've launched 53 new SKUs, with up to 14 more in the pipeline expected to launch before the end of February. We continue to see dried flower and pre-rolls as the two largest categories in the Canadian rec market. And based on US legal state data, we believe they will continue to dominate the foreseeable future even as alternative product forms gain traction.

[Derrick West:]

Thanks, Greg. Starting with our financial position, we ended the quarter with CAD 134 million of cash and short-term investments. On December 1, we used CAD 55 million to pay down our term loan to CAD 60 million, which left us with a pro forma cash and short term investment balance of CAD 79 million. The repayment on our term loan was agreed as part of the amendment and restatement of our credit facility completed during the quarter.

[Gregory Engel:]

Thanks, Derrick. The industry continues to make progress with the latest run rate estimated at CAD 3.2 billion for the rec market based on Stats Canada data for October 2020. A large driver of the growth is coming from the increase in the number of retail stores, mostly in the province of Ontario. Since July, the store count in the provinces grew by approximately 47% to 1,414 stores as of last week, driven by Ontario's cannabis retail stores more than tripling to 330 stores. And in early December, Ontario announced it was doubling the number of store authorizations again to 80 per month. Outside of Canada, we continue to serve international markets, including Israel and Australia, via export permits and look to expand international sales channel. Finally, I'd like to make a few comments about the United States because recent developments are significant for cannabis. As everyone's likely aware, the US election results, and particularly the Georgia runoff elections that tipped Senate control to the Democrats, is positive for pro cannabis initiatives. While we believe the timing of full legalization is unclear and will likely still take considerable time to happen, it is clear the political landscape has changed. We've patiently followed the market, and in particular exploring paths to enter the CBD market. To date, we have not found opportunities that meet our risk reward criteria, but we continue to monitor closely. Many of the R&D initiatives and new products that we work on, we believe, will ultimately be commercialized in US CBD markets and ultimately THC markets when federally legal. For example, our Edison RE

[Operator:]

. And your first question here comes from the line of David Kideckel from ATB Capital Markets.

[David Kideckel:]

Congrats on the quarter. Just looking at your gross margin profile here. Greg, I'm wondering if you can comment, just over the next several quarters – and knowing that that you won't be providing formal guidance here. Just with respect to product mix, whether it's value or your premium segment, 2.0 versus 1.0 products, how should we think about the overall splits in revenue, just so we can get a better grip here on gross margin.

[Gregory Engel:]

It's a great question. So, certainly, as we indicated, dried flower makes up the greatest proportion of our revenue. And over the last couple of quarters, the value segment has been a higher proportion over those two quarters than we'd seen in the past. As I alluded to earlier, one of our keys is our genetics program and introducing new cultivars. So, we did introduce three new cultivars in late December, Black Cherry Punch, I.C.C and Slurricane, as I mentioned, and we have plans to introduce additional new products under Edison coming forward. So, those new higher THC new genetics in the Edison banner are of higher margin because they have a higher average selling price. So, that's been a big shift for us. It's important to note as well, while in a couple of quarters – previously, we had reduced pre-roll production due to COVID, we were able to start ramping pre-roll production up, but those do also have a lower margin than Edison, for example. One big advantage for us, as I mentioned earlier, as well going forward is that we have new automation equipment, we expect to be fully commissioned and operational by the end of this quarter, early Q3, which, again, will reduce the cost of goods on pre-rolls and allow us to not only be efficient in the pre-roll production. But as our plan evolves, what we're looking to do is continue to increase SKU size and efficiency and margin by going to higher volume. I talked earlier about on our Trailblazer vape carts going to a 1g. On the pre-rolls, we're going to multi packs as well, which we've seen very good consumer response from. And I think when you look at our overall picture, one of the things that's impacted us certainly is – the good news on the genetics program is that we've really been able to sort through and come up with these new products, but it does have an impact. In the near term, as you're working on a number of different new genetics and getting through that genetic mix until you optimize the conditions takes time. So, we're confident that we're going to be able to continue to prove that on a go forward basis. I think one of the other things that's really impacted us, as we said, we're in the process of staffing up because we were producing less than the market demand for our products, which is good news in terms of on a go forward basis. So, increasing that will reduce – this isn't gross margins, specifically, but will reduce some of the unabsorbed overhead and adjusted EBITDA and really optimize and continue to improve efficiencies. And that's one of the keys for us as an organization. We've proven in the past that we can run very efficiently. And now with kind of scaling back up, we believe that will be the case going forward. And the last thing I'd say, David, is just that we also have a packaging taskforce that's been working over the last two quarters to look at other opportunities for cost reductions. And I think one of the key – we've identified a number of key areas, to bring by Q4, some of those initiatives into place to really have an impact on efficiencies in packings. So, just I guess in summary, I would say that, ultimately, we believe that our investments, as I said, in these new strains and new genetics to really meet the consumer demand are going to pay off, but it takes time to get there.

[David Kideckel:]

My follow-up question has to do with kind of in the month of December and given these unusual times of COVID, but have you noticed any seasonality effects, and in particular, have any particular products within your 2.0 product portfolio, whether that's chocolates, vapes, or beverages, have any of those products kind of stuck out to you just from a consumer overall revenue perspective during the month of December and even in two weeks of holidays?

[Gregory Engel:]

Yeah, no. It's a good question, David. Certainly, it's too early to tell on our RE

[David Kideckel:]

Congrats on the quarter.

[Operator:]

Your next question comes from the line of Andrew Partheniou from Stifel GMP.

[Andrew Partheniou:]

Maybe if we can continue the conversation on gross margin I think you mentioned the restaffing activities only benefit gross margin in Q3. But unabsorbed costs could be reduced in Q2. Just wondering if restaffing activities are the main source of the unabsorbed costs and lower production utilization? Could you provide a little bit more detail and reconcile these two items?

[Gregory Engel:]

Yeah, maybe I'll turn that over to Derrick to answer that question.

[Derrick West:]

During the quarter, we had unabsorbed overhead fixed costs, essentially depreciation insurance and taxes of CAD 2.7 million. And that was as a consequence of operating at the capacity level we have, which was approximately 40% during Q1. As we add to our planning and cultivation and then add the staff, we would be utilizing more of the rooms. And as a consequence, as it relates to our overall margin, a lower dollar amount of these unobserved overheads would impact Q2 as well as Q3. They would be staggered in terms of the direct benefits, but there would be some benefits in terms of the overall direct charge to the cost of sales during the second quarter. But to Greg's point, on an overall basis, the costs and production of that go into your inventory really normally impact the subsequent quarters' margins and cost of sales. And that was why he is providing perhaps a comment that the true benefit of operating at a higher level and getting a lower cost per unit starts to impact Q3 and later quarters.

[Andrew Partheniou:]

And kind of on the same line, we noticed that – you talked in the past that you're planning on lowering yields to increase quality. So, when you combine the lower yields, but also the higher margin new Edison strains, and obviously, taking into context that you won't be providing any kind of formal guidance, around what levels do you think we can see gross margin stabilizing? Do you have any internal goals in this metric? And maybe as part of that, can you also remind us where your production levels were before restaffing activities and what kind of increase we can expect once you're fully staffed?

[Gregory Engel:]

Maybe I'll start off and answer that, Andrew. I think, again, when we commented before that our – we knew we would be decreasing yields on a per gram basis – and part of that, also keep in mind because of COVID and the amount of inventory we had of extractable product and concentrates, we also stopped harvesting trim, right, in Q2 of 2020, which made up 30% of the product or material from the plant. So, that had an impact on our overall yields to begin with. We knew to optimize THC, we would have to kind of work to optimize yields, and it wasn't necessarily improving TFC, as I said. It was that investment in genetics. You don't have the ideal conditions. You know that impacts the drop. And it takes a number of different rooms and cycles to really get to the point. We are seeing yields improving over the last quarter, certainly, along with THC levels. So, we've been able to continue to see progress in both areas, as you can see by the product launches that we've recently had in that 23% To 27% THC range. And yields are starting to go back up. I don't want to give a kind of necessarily a specific target relative to where we need to be on a yield per THC basis because every strain is different and you have to treat them accordingly. And there is room depending on the strain to have some differential pricing as well for the product based on the demand. One comment I would make before answering the second part of your question also is that we returned – we started using street names in the marketplace and it's actually had a very positive impact in terms of response. People know the strains. We've seen the legal market attract a lot of people from the illicit market. And that's been very, very helpful for them to identify the products, and certainly something that's been a positive move. I think Derrick just now indicated, in answer to the second part of your question, that when we look at our facility utilization, prior to staffing up, we had about a 40% utilization rate of the facility. So by adding these 100 cultivation and 30 packaging people, again, this will be staggered in over time, we expect to continue to progress on that. It's not only just a Q2 initiative as we see opportunities not only domestically, but internationally growing an opportunity to continue to expand and increase cultivation levels going forward.

[Operator:]

Your next question comes from the line of Aaron Grey with Alliance Global Partners.

[Aaron Grey:]

First of all, for me, it's kind of – I want to go back to the commentary made kind of around the US and kind of how you're looking at it because, obviously, been a lot of focus on that, given the election results. So, you've seen some of your peers kind of get into the US market via CBD, MSOs, or other CPG businesses. So, just curious, as you kind of talked about not liking some of the risk-rewards you're seeing right now, could you kind of give some more color in terms of what you believe might be the best way to play it today, given there's still uncertainty in terms of whether there will be federal laws passed and how those federal laws will look. And if you're now kind of thinking about play the wait and see game to see how it evolves? Or if you might be a little bit more aggressive in terms of making a potential move into the US?

[Gregory Engel:]

It's a great question. I think, as I alluded to, one of our focuses has been always our focus and investment in R&D in developing new and differentiated products because, again, ultimately, we believe, in order for the legal market to displace the illicit market, whether or not that's in Canada, in the US or in other jurisdictions, offering differentiated products that change the whole cannabis consumer experience is going to be important. So, that's why products like our RE

[Aaron Grey:]

And then, second one would be specifically kind of around the province of Ontario. And obviously, everyone's looking for a lot more stores to come online in 2021 and we've started to see towards the end of 2020. So, just curious, from your perspective, in terms of like, as incremental stores come online, how are you seeing in terms of like saturation within specific geographies, right? So, I know there's some cities – in Toronto where there's a lot of retail stores in one specific area. So, do you feel like that might start to impact maybe the incremental dollar sale we're going to be seeing per new store that you're seeing in Ontario? And how do you feel like that might impact kind of the overall competitive landscape for you guys going forward? Thanks.

[Gregory Engel:]

No, yeah. It's a great question, Aaron. I think you're bang on in terms of not every new store is the same in terms of the ability to generate additional revenue. I think what you're seeing – for example, you referenced in Toronto, there's a couple key areas in Toronto along Queen Street, along Yonge Street that are two of the major arteries where there is an abundance of stores going in, and so that does lead to some level of saturation. So, it will grow the overall market, but at the same time, the revenue per store will not be at the same level because of that saturation point. I think when you look outside of the core of Toronto, there are certainly lots of opportunities, and we are seeing new stores happen in areas that have limited stores or no stores today. And I think that's been one of the keys. And I think that's where the growth opportunity certainly exists is to kind of – people that have had to rely upon online only sales, getting access to a store or multiple stores now is one of the key facets. So, it's a bit of combination of both, but certainly – and I look at Alberta as an example where with the number of stores, Alberta has the highest number of stores per capita right now, is that they probably did reach a saturation point kind of last year, and we've seen where a small number of stores and then optimization. So, Ontario is a long way away from that happening because there's still tremendous room for growth. And in terms of where we see the growth happening, but again, certainly along a couple of quarters, there is some saturation happening. The other area I would comment on is – there are still a couple of municipalities, especially in and around Toronto, that don't allow cannabis stores. So, if you recall, when legalization happened, the Ontario government allowed each municipality to opt in or opt out. I think, certainly, smart retailers should be looking to put stores on the border of the kind of those municipalities and I think that's kind of one of the opportunities that exists right now, especially kind of north of Toronto. There's a there's a big opportunity where some border stores along Steeles Avenue, for example, would have a huge impact on revenue.

[Operator:]

Your next question comes from the line of Graeme Kindler with Eight Capital.

[Graeme Kindler:]

I wanted to ask a follow up with respect to the adjusted gross margin. And I appreciate the comments made in prepared remarks and the discussion earlier in terms of the unabsorbed fixed overhead. I wanted to dig a little deeper. Greg, you mentioned on the call that you're going to be bringing in a pre-roll machine in the middle of the year and the Packaging Task Force is expected to complete their work by the end of the year. Can you give any indication of what those initiatives will do discreetly for the gross margin? Maybe there's some internal modeling you've done there and compare that to what the baseline is right now? That would be helpful. Thank you.

[Gregory Engel:]

Graeme, I don't want to give guidance necessarily specifically about the impact. I will give a comment on the pre-roll equipment. That equipment's been on site now. We've been working with it and we have seen, during test runs, it producing 40 to 50 pre rolls per minute and reducing labor required with pre roll production from 22 people down to 3. So, that's an example of just directionally what we've seen now. It's not fully optimized. We're still playing around with the blends in terms of the appropriate blended mix of material for it, but we expect that to have a significant impact in the near term. And then, part of our shift for Q4, as I said, is really looking at some of the shift in some of our packaging types and designs and trying to be more consistent in terms of utilizing a couple of pouches, for example, for multiple different product lines, which allows us not only efficiency and packaging, but also allows us in terms of packaging inventory and always availability. One of the things I commented on in the prepared remarks was we left revenue on the table in the quarter. We did not have sufficient product and/or capacity and staffing to meet the demand for our product, which is why we're staffing up. I don't want to give specific direction in terms of what we expect on savings. We have done modeling, but until we get to the point where – one of the challenge always with automation and equipment is until you get it commissioned and up and running, you don't know what impact it's going to actually have.

[Graeme Kindler:]

Perhaps then in terms of order of magnitude and what your expectations are between increasing your staffing levels, which are going to give you higher throughput there and then the pre roll initiative, the packaging initiatives, can you give any sense directionally in terms of what you're expecting will have the most outsized impact in terms of increasing the gross margin there?

[Gregory Engel:]

Again, directionally, I would say, it's definitely a combination of both. I think increasing staffing and increasing output and throughput is going to have the most significant impact because, again, producing more sellable product, especially as we've now optimized conditions around some of these new high THC genetics will create significant opportunities for us and the initiatives on packaging are more of a longer-term impact and we'll have an improvement in margin. But at the end of the day, increasing revenue on a high THC product which has a higher margin is going to have more impact.

[Operator:]

Your next question comes from the line of Adam Buckham with Scotiabank.

[Adam Buckham:]

First, in terms of the capacity, is it possible to speak to the potential size of missed revenue opportunities in fiscal Q1 as a result of production constraints? Maybe in terms of missed purchase orders or something along those lines?

[Gregory Engel:]

Internally, we do know – some of these purchase orders, we were able to fulfill in Q2, so they weren't necessarily completely missed. But we did have between $5 million and $6 million of POs we were not able to fulfill in the quarter.

[Adam Buckham:]

Secondly, in the prepared remarks, the team indicated that there could be some cooling off in the market, given the retailer shifts in Ontario. To date, have you seen any impacts in your buying patterns from the OCS? And then just a bit of a follow up to that, the OCS has recently had some comments that they're potentially rationalizing SKU counts? Obviously, OGI has already gone through this with much of its portfolio, but with this potentially coming, do you think it could eventually be a bit of a tailwind for the products there that are left remaining on the OCS?

[Gregory Engel:]

It's a good question. So, to answer your first question, I think certainly we have not seen a shift in order patterns, but certainly we've been notified by OCS, again, as they are continuing to kind of monitor daily, weekly the impact of now going to click and collect and local delivery only will have on retail sales that they could change. So, an existing PO, for example, that's due to be shipped three weeks out could be reduced. So, we have not seen that happen yet. But they've given us indication that that could happen. To your point, we've been probably one of the most active companies and working closely with OCS in terms of revamping our portfolio, switching our products. So, certainly, that's been a big focus for us. And we really see with every province and certainly with the two largest provinces, for us and for the market, Alberta and Ontario, we've been active in doing that. So, I think it does – their strategy, they're going to 100 core listing products. They expect those products to always be 100% available. And so, there are tailwind opportunities for those products, for core listed products to generate revenue because, again, the commitment from every company will be to make sure those products are always in stock. And there's tremendous opportunity. So, retailers know that they will always be able to access those products and carry them at the retail store. But any listing requirement in the province of Ontario now will require a 98.5% inventory level. And so, it's critical for companies to consistently meet that level or you run – as you would see in any normal retail environment, you run the risk of being delisted. So, companies that have in demand products and are able to consistently supply the market are in a great position in terms of revenue against those products.

[Operator:]

Your next question comes from the line of John Zamparo from CIBC.

[John Zamparo:]

I wanted to get a sense of how you feel about the balance sheet at the moment. And, of course, you did the recent equity raise, but there's still some debt on the balance sheet and industry valuations are pretty robust at the moment. And now, there's the prospect potentially of entering US, at some stage, at least. I just would like to get your thoughts on capitalization levels at this time.

[Gregory Engel:]

We're very comfortable with our balance sheet, as you said. At the end of the quarter, after using CAD 55 million of proceeds to pay down a portion of the debt facility, we still have CAD 60 million remaining in debt. But we did have CAD 79 million in cash and short term investments, plus CAD 8 million of restricted cash. And again, one thing that I would highlight is, we had the second of the last three quarters positive cash flow from operations. So, as a company perspective, I think we're in a strong position on a go forward basis relative to our own cash position and also kind of how we're operating and our operating consistency.

[John Zamparo:]

And then my follow up is on the gross margin. When you think about getting back to the previous level, kind of that 35% to 40% number, do you need to get to the same level of net cannabis revenue, probably about CAD 25 million plus in terms of sales, or is your cost structure different now that it wouldn't quite need to be so high? Or is it potentially higher because now you're offering a lot more value products? Just would like to get a sense of what you'd need to hit on the top line to hit that previous gross margin level?

[Gregory Engel:]

I think there is a mix there. So, certainly, on one hand, we have become much more efficient as an operator. I hate to say there was a benefit from COVID. But one of the things that with reduced staffing it forced us to do was look at how we operate, how we do things, and we've been able to get much more efficient in a lot of things we do. And then kind of going forward, as I said, some of the initiatives we've taken on, automation, or even kind of systems and how we operate. So, do we need to be there? I think yes. There's no question that our mix is – I didn't mean to say, do we need to be there; yes, at the same level of net revenue. I think it's a mix, right? Because we are selling more value, large volume SKUs, so your average price per gram there, certainly, is lower, but your labor costs would go into that and packaging costs are significantly lower as well. But again, our goal is to – as I spoke to earlier, is to really continue to drive more revenue on the high margin products. And that's why this investment in the genetics program and what we've been doing over the last 12 to 18 months is – it's really starting to pay off now because that is going to be critically important. We have seen – there's no question, we've seen price compression in many categories. And it's not just value dried flower categories. It's also been in the vapes category as well. So, again, I don't want to give a specific forecast, as we don't give guidance on what level we need to hit, but I guess your comment would be accurate in terms it's a mix between the two. On one hand, we're selling more of the high volume, lower price value products, which do have a lower margin. One of our lowest margin products historically has been pre-roll. So, we're looking to improve that dramatically with the automation.

[Operator:]

Your next question comes from the line of Vivien Azer with Cowen and Company.

[Vivien Azer:]

I just wanted to follow-up on Aaron's question about the US market and your posturing there around CBD. There hasn't been a lot of evidence around brand equity transferability between CBD and THC. And frankly, the category development in CBD has been quite lackluster, and there continues to be regulatory uncertainty around the FDA. So, can you just expand on why that's the appropriate pathway to enter the US? I understand, obviously, the regulatory constraints around THC. But why are you going to pursue a CBD strategy?

[Gregory Engel:]

It's great question, Vivien. Ultimately, what you had outlined is why we have not entered the US and we have not seen really an impact. Is there transferability between CBD and THC products? Not necessarily. I think there's only a few areas where that's the case. I think for part of us, our strategy there was, as we've evaluated entering the market is, simply to get a toehold in the US and look to be a US operator and kind of look to hire people potentially or acquire a company that you could leverage across to the THC market. But I agree with you 100% that to date we haven't seen that transfer. And ultimately, that's why we haven't made the decision. Again, our focus has been, as I outlined earlier in response to Aaron's questions, I think there are technologies and innovations, like our dried powder, that can be applied in both markets. And one strategy may be to say, do we look for someone to license those to or do we look to launch those ourselves? I think there is still a level of uncertainty on CBD in the US with the FDA. I think there is still going to be guidance out where they are going to look at certain forms of ingestion. For example, oral ingestion products having to undergo some toxicology work potentially. So, the rules still aren't clear on CBD. And there's a number of reasons we have not yet entered the market. But certainly we've looked at it as an opportunity to tip into US possibly.

[Operator:]

Your next question comes from the line of Rahul Sarugaser from Raymond James.

[Rahul Sarugaser:]

My first question is around market share. And all your comments earlier are well taken. I guess maybe more – since speaking more at the macroscopic level, we've seen a decline in market share over several quarters. At least in this last quarter, we've seen that being attenuated somewhat, so you are stemming that. Given your earlier comments about increasing appreciation and demand for OrganiGram's products, do you anticipate that you kind of bottoming out and market shares should start to – that should start to increase over time?

[Gregory Engel:]

As I mentioned, we had unfulfilled POs in the quarter. There's no question. And I think one of the challenges we've had truly is we've had inconsistent supply of many of our products. So, even our Trailblazer Snax, when it was launched in chocolate category, it was not always available. And part of the challenge we face is that in certain jurisdictions in terms of how much product they carry at launch, and then if it sells out quickly, our SHRED is very similar to that. Right? So, SHRED was an overwhelming success. They said it was the most searched – number one most searched brand in November, December on the OCS website. And so, we had no idea that was going to be the case. So, again, it's difficult to just look at our share because there's kind of the lost opportunity there, where we've not been able to fulfill the market demand. And I think, certainly, we believe with increased production, we are in a great position to be able to continue to increase share on products like that or some of our core new offerings on Edison because every time we ship SHRED in, it sells out very quickly right now. And as I said, the search metrics that we've seen on OCS would be an indication of the demand. So, what you see in terms of share doesn't represent the demand necessarily. We've got to do a better job in kind of meeting the inventory levels to fulfill that demand.

[Rahul Sarugaser:]

Just a quick follow-up and testing a little bit. So, you are one of two companies that has taken a pretty material debt in biosynthesis and we're seeing the States really starting to evolve. And given that that is in Hyasynth and its specific, somewhat unique strategy focusing on the major cannabinoids relative to its universe of peers which are very focused on the minor cannabinoids, do you see this as kind of your ace in the hole, particularly when it comes to entering the US market and, as you referred to, specifically around the beverage powders?

[Gregory Engel:]

I'd agree in part with what you said. Like initially, certainly, Hyasynth's approach has been – they were the first commercial company that we're well aware of – first biosynthesis company to have a commercial sale of a cannabinoid with CBDA produced through biosynthesis. But they are focused on minor cannabinoids as well. They've got a fulsome portfolio of 23 cannabinoids, 19 minor and 4 major cannabinoids. Again, I think one of the keys of early focus on major cannabinoids is that the process for producing them is somewhat more straightforward and not as complicated. But in parallel, they are also working on minor cannabinoids and I think that's going to be critical for the future. And I wouldn't necessarily agree with your comment that like every other companies are all focusing on minor, we've seen other companies talking about plans to commercialize CBD in the near term and that's been their focus. But I think Hyasynth's focus, they've got a – our investment strategy with them is then – we believe they have a strong IP portfolio and that they are working on dual paths, both with major cannabinoids, but potentially for minor cannabinoids in the future and I think that's one of the key aspects where we believe, in the future, minor cannabinoids are going to benefit greatly from biosynthetic production because, ultimately, you cannot produce the majority of minor cannabinoids from a plant in any significant level and the cost would be cost prohibitive. So, the benefits of biosynthetic production, as you know, are much higher with minor cannabinoids than major cannabinoids.

[Operator:]

Your next question comes from the line of Pablo Zuanic.

[Pablo Zuanic:]

Two quick questions. One, when you see Aphria and Tilray merge, how do you think about that? You have about 3%, 4% share based on my numbers. As the industry starts to merge, is that a problem for a company like yourselves? Or how does that manifest itself at the ground level? Or it doesn't make a difference? It's not something that's keeping you awake at night? And the second question, in the case of Israel with Canndoc, there's been two or three other companies that have also shipped to Israel since Canndoc is, like you said, cherry picking and they buy something from some companies and other things from other companies. Just talk about the dialogue in terms of what are they buying from you and what is it that stands out compared to what other people are exporting to Israel?

[Gregory Engel:]

Pablo, your first question, in terms of the overall marketplace, I think we have seen – bigger doesn't necessarily mean better. Some of our larger peers have shuttered multiple facilities. So, a potential merger of the Aphria and Tilray coming together, it may be more about international markets from certainly what I've seen written or kind of looking at other markets than it is about the Canadian market per se. Certainly, at least that's many analysts' perspective on it. I think for us the key has to be continue to drive forward with new and innovative products, differentiated products that there is market demand for and that's going to be one of the critical parts. To answer your question on Israel, certainly for us, with Canndoc, we're an indoor producer and certainly there's a differentiation between their other supplier at this point in terms of the marketplace. And certainly, the initial response to the product we did sell in on our first shipment was extremely positive. And we're working hard with Canndoc to be able to continue to supply them in Q3. And again, that will be dependent upon getting the CUMCS certification, as well as having the right product mix for them at the time. But certainly, for them, one of the big advantages that they saw in us is being an indoor producer.

[Operator:]

And there are no further questions at this time. Ladies and gentlemen, this concludes today's call. We thank you for your participation and you may now disconnect.